TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note published on Friday,Benzinga reports. They currently have a $3.00 price objective on the stock.

TransCode Therapeutics Stock Performance

Shares of NASDAQ RNAZ opened at $0.33 on Friday. The business has a 50-day simple moving average of $0.49 and a two-hundred day simple moving average of $0.69. TransCode Therapeutics has a 52 week low of $0.22 and a 52 week high of $18.66.

Institutional Trading of TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,138 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.